Ideal Cures adds new manufacturing facility at 'tax holiday' location

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/hansslegers)
(Image: iStock/hansslegers)

Related tags Industry

Ideal Cures has added a fourth manufacturing location at Sikkim in India to meet the demand of its local customers and to expand its global customer base.

Ideal Cures has added a fourth manufacturing location at Sikkim in India to meet the demand of its local customers and to expand its global customer base.

Dr. Kamlesh Oza, President Global Business Development told us that Idea Cures has “followed the high concentration of pharmaceutical industry manufacturing locations in Sikkim, which has been promoted as a tax holiday for the industry​.”

According to Oza, the company expects production demand for the domestic markets in India to shift to Sikkim, “as that’s where the industry will enjoy a tax holiday so that they can remain competitive in a price sensitive and controlled environment in India​.”

Oza added that “some of the lowest prices for pharmaceuticals in the world are in India​.”

As such, the company expects production to “ramp up​” at this location as the industry moves production from the other areas. “Eventually the infrastructure in the region will improve and make way for converting the manufacturing here from domestic to export markets for the western world​,” said Oza.

According to Oza’s count, there are more than 30 companies in the state, but it is a remote place and one that is difficult to access from the industrialized parts of India.

In order to deliver at the doorstep and convenience our customers who would otherwise need to carry larger inventories and put up with long lead times we decided to put up our plant in close proximity to our customers​,” he said.

The cGMP facility is currently under construction and is expected to become on line in the first quarter of 2017.

Oza added, “Our plans are to make this a state-of-the art facility to not only produce for the region but also export to nearby countries such as Nepal and Bangladesh which are in close proximity initially and be the backup for our plants in Jammu and Vasai which will be focused on exports to the western pharmaceutical industry​.”

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars